Myriad Genetics, MYGN

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...
Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $16 from $21 and keeps an Equal Weight rating on the shares after ...
UnitedHealthcare will stop covering Myriad Genetics' GeneSight test in 2025, impacting $45 million in revenue. Myriad ...
Myriad Genetics Chief Executive Paul J. Diaz will leave the company April 30 to return to private equity firm Cressey & Co., where he will be a managing partner. The former Kindred Healthcare CEO was ...
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics ...
SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of Directors ...
Good day, and thank you for standing by. Welcome to the Myriad Genetics Fourth Quarter 2024 Financial Earnings Conference Call. At this time, all participants are in a listen-only mode.
Short sellers have been increasing their bets, with short interest now accounting for 6.1% of the stock's available float.